The COVID-19 pandemic has created a seismic upheaval in global health care and individual health testing and treatment. Previous gains in reducing life-threatening chronic diseases are being eroded by the need to turn attention and resources to the pandemic. It feels like a “Snakes and Ladders” board game: The counter has landed on the head of a snake and programs for other diseases have slid to the bottom of the board, landing many years behind.
Tagged: noncommunicable diseases
A version of this post originally appeared on FHI 360’s R&E Search for Evidence blog.
Known around the world, Prof. Peter Lamptey is a global health champion in any light. Many of you may know him from his early involvement in the global HIV response or from his fight to raise public awareness of noncommunicable diseases (NCDs). I first heard Prof. Lamptey speak about the role of laboratory science in the NCD response at a conference plenary hosted by the African Society for Laboratory Medicine, my former employer. A compelling talk for sure, but notably his plenary was also my first significant introduction to FHI 360’s research.
On April 15, 2014, FHI 360 and its partners hosted a one-day symposium to discuss challenges and opportunities faced by the noncommunicable diseases (NCD) and HIV/AIDS global communities. Our co-host was the London School of Hygiene & Tropical Medicine (LSHTM) Centre for Global Non-Communicable Diseases. Other collaborators were the Joint United Nations Programme on HIV/AIDS (UNAIDS) and the University College London (UCL) Grand Challenge of Global Health. FHI 360 experts who spoke include:
- Peter Lamptey, MD, DrPH, MPH, Distinguished Scientist and President Emeritus
- Timothy Mastro, MD, DTM&H, Director, Global Health, Population and Nutrition
- Tricia Petruney, MA, Senior Technical Officer
- Kwasi Torpey, MD, PhD, MPH, Technical Director, Strengthening Integrated Delivery of HIV/AIDS Services, Nigeria
View the presentations from the symposium to hear our experts’ and partners’ perspectives on how these different disease communities can work together for more common, efficient and cost-effective strategies in the prevention and control of NCDs and HIV.